

Paula Rodriguez-Otero

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/113302/publications.pdf>

Version: 2024-02-01

11
papers

924
citations

1163117

8
h-index

1281871

11
g-index

11
all docs

11
docs citations

11
times ranked

971
citing authors

#	ARTICLE	IF	CITATIONS
1	Patient-reported outcomes in relapsed/refractory multiple myeloma treated with melflufen plus dexamethasone: analyses from the Phase II HORIZON study. <i>British Journal of Haematology</i> , 2022, 196, 639-648.	2.5	7
2	Circulating Tumor Cells for the Staging of Patients With Newly Diagnosed Transplant-Eligible Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2022, 40, 3151-3161.	1.6	40
3	Melflufen and Dexamethasone in Heavily Pretreated Relapsed and Refractory Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2021, 39, 757-767.	1.6	98
4	Pomalidomide, Cyclophosphamide, and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma: Real-World Analysis of the Pethema-GEM Experience. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, 413-420.	0.4	6
5	Roadmap to cure multiple myeloma. <i>Cancer Treatment Reviews</i> , 2021, 100, 102284.	7.7	44
6	Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. <i>Lancet Oncology</i> , The, 2020, 21, 207-221.	10.7	544
7	Melflufen for relapsed and refractory multiple myeloma. <i>Expert Opinion on Investigational Drugs</i> , 2020, 29, 1069-1078.	4.1	17
8	Circulating tumor cells for comprehensive and multiregional non-invasive genetic characterization of multiple myeloma. <i>Leukemia</i> , 2020, 34, 3007-3018.	7.2	26
9	Single-Institution Experience in Clinical Trials During the COVID-19 Pandemic in Spain: Not So Bad After All?. <i>JCO Global Oncology</i> , 2020, 6, 904-905.	1.8	3
10	Randomized Phase 2 Study of Weekly Carfilzomib 70 Mg/m ² and Dexamethasone Plus/Minus Cyclophosphamide in Relapsed and/or Refractory Multiple Myeloma (RRMM) Patients (GEM-KyCyDex). <i>Blood</i> , 2020, 136, 8-9.	1.4	12
11	First Clinical Study of the B-Cell Maturation Antigen (BCMA) 2+1 T Cell Engager (TCE) CC-93269 in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Interim Results of a Phase 1 Multicenter Trial. <i>Blood</i> , 2019, 134, 143-143.	1.4	127